Pharmaceutical industry – Page 22
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
BusinessSmall biocides companies face uncertain fate
Cost and complexity of European law hampers innovation and excludes SMEs
-
BusinessCancer immunotherapy spreads rapidly
New approvals and expanded use for checkpoint inhibitor drugs illustrate the power of Nobel-winning science
-
OpinionThe projects drug companies wish they’d never started
Failures are common in drug research, but some are bigger than others
-
ResearchRemote controlled self-optimising flow synthesis
Online interface could allow virtual sharing of complex kit, and enable simple improvement of reaction conditions
-
ArticleContinuous manufacturing could revolutionise drug development
Continuous flow manufacturing of pharmaceuticals offer the flexibility to accelerate the drug development process
-
BusinessCleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
BusinessIndia moves to ban cocktail drugs
Government injunction on 328 fixed dose combinations is strongly opposed by manufacturers
-
-
BusinessLandmark China cancer drug full approval ‘first of a wave’
Chi-Med’s fruquintinib is a result of China’s evolving drug innovation and regulation
-
NewsBitter feuding at Cochrane healthcare audit body paralyses organisation
One member has been expelled from the governing board while another four resign with accusations of pharmaceutical industry bias flying
-
BusinessBuilding resilience to climate threats
As extreme weather events become more frequent, chemical and pharmaceutical producers are taking steps to fend them off in future
-
ResearchGenentech antibiotic quells resistance
Modified arylomycin combines high potency with new mechanism of action
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
BusinessUS court overturns plant safety rule delay
Appeal finds Trump’s postponement of the 2017 Chemical Disaster Rule was unlawful
-
OpinionFeeding the confusion
When it comes to working out what foods do to our bodies, mostly we just don’t know
-
OpinionBehind enemy lines
When trade war breaks out, globalised industries ship out to dodge tariffs
-
BusinessUS approves first RNA interference drug
Alnylam’s Onpattro (patisiran) can treat a rare hereditary disease by silencing a specific gene